Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 31;19(8):2244.
doi: 10.3390/ijms19082244.

Anti-TNF Therapy in Crohn's Disease

Samuel O Adegbola  1   2 , Kapil Sahnan  3   4 , Janindra Warusavitarne  5   6 , Ailsa Hart  7   8 , Philip Tozer  9   10
Affiliations
Review

Anti-TNF Therapy in Crohn's Disease

Samuel O Adegbola et al. Int J Mol Sci. .

Abstract

Crohn's disease (CD) accounts for a variety of clinical manifestations or phenotypes that stem from chronic inflammation in the gastrointestinal tract. Its worldwide incidence is increasing including younger or childhood-onset of disease. The natural history of Crohn's disease is characterized by a remitting and relapsing course that progresses to complications and surgery in most patients. The goals of treatment are to achieve clinical and endoscopic remission, to avoid disease progression and minimise surgical resections. Medical treatment usually features antibiotics, corticosteroids, immunomodulators (thiopurines, methotrexate). Anti-TNF (tumour necrosis factor) therapy was approved for use in Crohn's disease in 1998, and has changed the paradigm of treatment, leading to improved rates of response and remission in patients. There are significant considerations that need to be borne in mind, when treating patients including immunogenicity, safety profile and duration of treatment.

Keywords: Crohn’s disease; anti-TNF; medical treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Molodecky N.A., Soon I.S., Rabi D.M., Ghali W.A., Ferris M., Chernoff G., Benchimol E.I., Panaccione R., Ghosh S., Barkema H.W., et al. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases with Time, Based on Systematic Review. YGAST. 2012;142:46–54.e42. doi: 10.1053/j.gastro.2011.10.001. - DOI - PubMed
    1. Gasche C. Genotypes and phenotypes in Crohn’s disease: Do they help in clinical management? Gut. 2005;54:162–167. doi: 10.1136/gut.2003.035600. - DOI - PMC - PubMed
    1. Sartor R.B. Mechanisms of Disease: Pathogenesis of Crohn’s disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006;3:390–407. doi: 10.1038/ncpgasthep0528. - DOI - PubMed
    1. Targan S.R., Hanauer S.B., van Deventer S.J.H., Mayer L., Present D.H., Braakman T., DeWoody K.L., Schaible T.F., Rutgeerts P.J. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med. 1997;337:1029–1035. doi: 10.1056/NEJM199710093371502. - DOI - PubMed
    1. Satsangi J., Silverberg M.S., Vermeire S., Colombel J.-F. The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications. Gut. 2006;55:749–753. doi: 10.1136/gut.2005.082909. - DOI - PMC - PubMed

MeSH terms